{
    "root": "a1dc858f-6aa7-4a25-a7bd-15a05aa4115c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ontruzant",
    "value": "20250311",
    "ingredients": [
        {
            "name": "trastuzumab",
            "code": "P188ANX8CK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_231601"
        },
        {
            "name": "trehalose dihydrate",
            "code": "7YIN7J07X4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_232797"
        },
        {
            "name": "histidine monohydrochloride monohydrate",
            "code": "X573657P6P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "histidine",
            "code": "4QD397987E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "polysorbate 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        }
    ],
    "indications": {
        "text": "ontruzant her2/neu receptor antagonist indicated adults : treatment her2-overexpressing breast cancer . ( 1.1 , 1.2 ) treatment her2-overexpressing metastatic gastric gastroesophageal junction adenocarcinoma . ( 1.3 ) select patients therapy based fda-approved companion diagnostic trastuzumab product ( 1 , 2.2 ) .",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "gastroesophageal junction adenocarcinoma (DOID:4944)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4944"
            },
            {
                "text": "adenocarcinoma (DOID:299)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_299"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "intravenous ( iv ) infusion . administer iv push bolus . ontruzant different instructions subcutaneous trastuzumab products . ( 2.3 ) substitute ontruzant ( trastuzumab-dttb ) ado-trastuzumab emtansine fam-trastuzumab deruxtecan . ( 2.3 ) perform her2 testing using fda-approved tests laboratories demonstrated proficiency . ( 1 , 2.2 ) adjuvant treatment her2-overexpressing breast cancer ( 2.2 ) administer either : initial dose 4 mg/kg 90 minute iv infusion , 2 mg/kg 30 minute iv infusion weekly 12 weeks ( paclitaxel docetaxel ) 18 weeks ( docetaxel carboplatin ) . one week last weekly dose ontruzant , administer 6 mg/kg iv infusion 30 90 minutes every three weeks complete total 52 weeks therapy , initial dose 8 mg/kg 90 minutes iv infusion , 6 mg/kg 30 90 minutes iv infusion every three weeks 52 weeks . metastatic her2-overexpressing breast cancer ( 2.3 ) initial dose 4 mg/kg 90 minute iv infusion followed subsequent weekly doses 2 mg/kg 30 minute iv infusions . metastatic her2-overexpressing gastric cancer ( 2.3 ) initial dose 8 mg/kg 90 minutes iv infusion , followed 6 mg/kg 30 90 minutes iv infusion every 3 weeks .",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "gastric cancer (DOID:10534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10534"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "Ontruzant is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ).",
    "contraindications_original": "For intravenous (IV) infusion only. Do not administer as an IV push or bolus. Ontruzant has different dosage and administration instructions than subcutaneous trastuzumab products. ( 2.3 ) Do not substitute Ontruzant (trastuzumab-dttb) for or with ado-trastuzumab emtansine or fam-trastuzumab deruxtecan. ( 2.3 ) Perform HER2 testing using FDA-approved tests by laboratories with demonstrated proficiency. ( 1 , 2.2 ) Adjuvant Treatment of HER2-Overexpressing Breast Cancer ( 2.2 ) Administer at either: Initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 12 weeks (with paclitaxel or docetaxel) or 18 weeks (with docetaxel and carboplatin). One week after the last weekly dose of Ontruzant, administer 6 mg/kg as an IV infusion over 30 to 90 minutes every three weeks to complete a total of 52 weeks of therapy, or Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks for 52 weeks. Metastatic HER2-Overexpressing Breast Cancer ( 2.3 ) Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. Metastatic HER2-Overexpressing Gastric Cancer ( 2.3 ) Initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks.",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Ontruzant",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_231601"
        }
    ]
}